AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05134090 — intervention group
Intervention type: DEVICE
Intervention: Ovaian tissue explant
Description: Ovarian tissue explant for cryopreservation of ovarian tissue
Study NCT06290063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fsCBD Cannabidiol
Description: Full Spectrum hemp-derived CBD (fsCBD; 200mg CBD/4mg THC) capsules produced by Ecofibre/Ananda Hemp will be used
Study NCT06290063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bsCBD Cannabidiol
Description: Broad spectrum hemp-derived CBD (bsCBD; 200mg CBD) capsules produced by Ecofibre/Ananda Hemp will be used
Study NCT06290063 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo arm; capsules produced by Ecofibre/Ananda Hemp will be used
Study NCT06396793 — intervention group
Intervention type: OTHER
Intervention: no intervention because it is an observational study
Description: it is an observational study thus there is no intervention
Study NCT05387226 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oncolytic Virus Injection(RT-01)
Description: RT-01 will be administered intravenously on day 1 and 6, and every 8 weeks thereafter (up to 6 times)
Study NCT05000892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab , Carboplatin, Nab-paclitaxel
Description: Patients receive Sintilimab IV on day 1, paclitaxel IV on day 1 and carboplatin IV on day 1 . Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
Study NCT05062083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11C-MC1
Description: Up to 20 mCi injected IV followed by PET scanning
Study NCT05062083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11C-PS13
Description: Up to 20 mCi injected IV followed by PET Scanning
Study NCT05062083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoprofen
Description: Ketoprofen 75 mg orally once
Study NCT05062083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: celecoxib 600 mg orally once
Study NCT04997928 — intervention group
Intervention type: OTHER
Intervention: Serum PAI-1 alpha analysis.
Description: After all four groups of patients have given their consent for the study, a sample of 5cc blood will be obtained once for the PAI-1 analysis.
Study NCT05914246 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VIOLA proximal seal
Description: VIOLA proximal seal system for maintenance of hemostasis when suturing the aortic anastomoses
Study NCT04201821 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: fecal microbial transplantation (FMT)
Description: Fecal microbial transplantation (FMT) is the infusion of intestinal microbiota from healthy donors.
Study NCT06099210 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Glasgow coma scale
Description: Closed tach brain injury due to external force was included according to the GCS score
Study NCT05121363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2858 injection
Description: TQB2858 is an anti-programmed death receptor 1(anti-PD-1) /Transforming growth factor-β(TGF-β )bi-functional fusion protein
Study NCT05121363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride capsules
Description: Anlotinib Hydrochloride is a multi-target tyrosine kinase inhibitor.
Study NCT05559021 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial Therapy Treatments
Description: • Myofascial approach: After the bibliographic review of myofascial therapy treatments in fibromyalgia patients based on the articles by CastroSánchez AM et al., and an expert consensus, the following approach was decided: patients would have 4 sessions in total with 1 session per week of 30 minutes each.~* Transverse planes in the thoracolumbar fascia (TCL) and abdomen: Performing a myofascial induction as described by Pilat.~* Transverse planes at C7-D3 and sternum: Performing a myofascial induction as described by Pilat.~* Suboccipital inhibition: Performing a myofascial induction as described by Pilat
Study NCT05559021 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive Mobilizations Approach
Description: • Approach with passive mobilizations: After the literature review of manual therapy treatments in fibromyalgia patients and a consensus of experts in Manual Therapy with more than 15 years of experience, the following approach was agreed upon by the expert: patients would have 4 sessions in total with 1 session per week of 30 minutes each.~* Postero-anterior cervical sliding~* Postero-anterior lumbar slippage~* Postero anterior dorsal slippage
Study NCT06371287 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treinamento Auditivo Musical
Description: Auditory training with a focus on musicality. The skills trained will be: figure-ground for instrumental sounds, sequential figure-ground, directed listening, duration of sounds, frequency of sounds, rhythm (temporal structuring), auditory closure and audiovisual memory, with a focus on temporal processing, working memory and attention selective on an increasing scale of difficulty. The frequency ranges of instrumental sounds are from 200 to 4000 Hz, composed of the following instruments: guitar, vibraphone, piano, flute and drum.
Study NCT06371287 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This placebo approach will be to demonstrate the influence of musical exposure without exercises with structuring auditory skills and compare with the TAM group.~The song Sonata for two pianos in D major, K448, by Mozart, will be used. The films selected were: Cirque Du Soleil, entitled The Journey of Man; Chaplin collection with the following films: Modern Times, The Great Dictator, In Search of Gold and Footlights. The choice of the order of the films will be random, as proposed by Freire (2009).
Study NCT05053802 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Microwave ablation plus Camrelizumab
Description: Tumor received treatment of microwave ablation and received no more than 16 cycles of Camrelizumab
Study NCT05053802 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Microwave ablation
Description: Tumor received treatment of microwave ablation
Study NCT05627206 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem Management + For Moms
Description: Psychosocial intervention conducted by a trained Wellbeing-Community health worker. Adapted from Problem Management +, thinking healthy and Strong Minds-Strong Communities intervention to target women with small children and mental health symptoms living in low-resourced settings. Combines several evidence-based strategies such us psychoeducational, motivational interviewing, cognitive restructuring and relaxation exercises. Organized in 10 weekly sessions (8 individual 2 in group) provided in-person, by phone or virtually.
Study NCT04793620 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TQL1055
Description: Semisynthetic saponin adjuvant
Study NCT04793620 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Acellular pertussis vaccine
Description: Acellular pertussis vaccine
Study NCT04793620 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Acellular pertussis vaccine
Description: Acellular pertussis vaccine
Study NCT05328583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS5685；Placebo
Description: Drug1: HRS5685 Single dose in group A-F and multiple doses in group G-H~Drug2: Placebo Single dose in group A-F and multiple doses in group G-H
Study NCT05207670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab (Cohorts A-C)
Description: Participants will receive SC mosunetuzumab for up to 17 cycles and for optional maintenance (Cohort A only)
Study NCT05207670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab (Cohorts D-E)
Description: Participants will receive SC mosunetuzumab for up to 34 cycles
Study NCT05207670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants can be treated with tocilizumab if they present with CRS after receiving mosunetuzumab
Study NCT06506461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: Given Subcutaneous (under the skin)
Study NCT06506461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Given Intravenous (IV)
Study NCT06506461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gene-modified CD34+ cells
Description: Given Intravenous (IV)
Study NCT04838769 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: REZŪM
Description: Subjects randomized to receive the REZŪM treatment will receive standardized treatment, following the Instruction for Use.
Study NCT04838769 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alpha blocker and 5-alpha reductase inhibitor
Description: Subjects assigned to dual drug therapy will be treated with the local formulary preferred choice of commercially available urinary selective alpha blocker and 5-alpha reductase inhibitor. This arm will therefore represent local standard of care.
Study NCT05590689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gliolan
Description: A repetitive dose of Gliolan will be administrated in combination with radiotherapy (radiodynamic therapy)
Study NCT05590689 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiodynamic therapy
Description: Radiotherapy will be performed in combination with Gliolan administration
Study NCT04886154 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: MenABCWY-2Gen low dose vaccine
Description: MenABCWY-2Gen low dose vaccine is administered intramuscularly in the deltoid region of the non-dominant arm as 2 doses to participants in the ABCWY low dose Group in study Phase I, ABCWY low dose_06 Group and ABCWY low dose_02 Group in study Phase II (Formulation and Schedule-finding) and as 2 doses to participants in the ABCWY low dose_01 Group, ABCWY low doseS_02 Group and ABCWY low doseS_06 Group in study Phase II (Sourcing).
Study NCT05614596 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CT guided and Flouroscopic guided injection of corticosteroid and local anathesia
Description: Patients will be grouped into two groups, the first group (Group A) included patients who were subjected to fluoroscopic guided injection, and the second group (Group B) will include patients who were subjected to CT guided injections.
Study NCT06425900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Winlevi (Clascoterone) cream 1%
Description: Dosed twice daily (BID)
Study NCT05164991 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visuo-tactile stimulations of the right hand
Description: Participants lay down in the magnetic resonance (MR) scanner are presented with visual stimuli (videos of the virtual rubber hand - visual stroking) simultaneously in real time with tactile stimuli (robotic stroking of the participant's hand - tactile stroking). An MR-compatible robot systematically provides the tactile stroking on the participant's hand. MR-compatible goggles show the visual stroking. Patterns of long and short robotic movements will be provided.
Study NCT04886154 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: MenABCWY-2Gen high dose vaccine
Description: MenABCWY-2Gen high dose vaccine is administered intramuscularly in the deltoid region of the non-dominant arm as 2 doses to participants in the ABCWY high dose Group in study Phase I, ABCWY high dose_06 Group and ABCWY high dose_02 Group in study Phase II (Formulation and Schedule-finding) and as 2 doses to participants in the ABCWY high dose_01 Group, ABCWY high doseS_02 Group and ABCWY high doseS_06 Group in study Phase II (Sourcing).
Study NCT04886154 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is administered intramuscularly in the deltoid region of the non-dominant arm as 2 doses to participants in the Placebo low dose Group, Placebo high dose Group in study Phase I and as 1 dose to participants in the ABCWY low dose_06 Group, ABCWY low dose_02 Group, ABCWY high dose_06 Group, ABCWY high dose_02 Group in study Phase II (Formulation and Schedule-finding).
Study NCT04886154 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is administered intramuscularly in the deltoid region of the non-dominant arm as 2 doses to participants in the Placebo low dose Group, Placebo high dose Group in study Phase I and as 1 dose to participants in the ABCWY low dose_06 Group, ABCWY low dose_02 Group, ABCWY high dose_06 Group, ABCWY high dose_02 Group in study Phase II (Formulation and Schedule-finding).
Study NCT04886154 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: MenB vaccine
Description: MenB vaccine is administered intramuscularly in the deltoid region of the non-dominant arm, whenever it's possible, as 2 doses in a 0,6-months schedule to participants in the Control Group in study Phase II (Formulation and Schedule-finding).
Study NCT04886154 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MenACWY vaccine
Description: MenACWY vaccine is administered intramuscularly in the deltoid region of the dominant arm as 1 dose to participants in the Control Group in study Phase II (Formulation and Schedule-finding).
Study NCT03998293 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Somatostatin
Description: infused to block endogenous insulin secretion over a 4 hour period
Study NCT05511896 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Repeated trunk flexion
Description: A 60-min intermittent trunk flexion protocol. Participants will sit on a standard height sit, with their knees bent at approximately 90° with their hands crossed on their chest. They will perform 40 sets of 60 s of maintaining a flexed position, interspersed with 30 s of rest. Participants will achieve the flexed position by tilting the pelvis posteriorly and leaning forward. During rest, participants will sit up straight without leaning on the support.
Study NCT06437964 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No use of prophylactic antibiotics
Description: In the endoscopic secondary prevention of cirrhotic patients with gastroesophageal variceal bleeding, do not use any antibiotics before the endoscopic operation.
Study NCT06437964 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No use of prophylactic antibiotics
Description: In the endoscopic secondary prevention of cirrhotic patients with gastroesophageal variceal bleeding, do not use any antibiotics before the endoscopic operation.
Study NCT06002750 — intervention group
Intervention type: OTHER
Intervention: disease
Description: Do you have dermatomyositis
Study NCT05651750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: receiving 2 months treatment with Montelukast once a day
Study NCT05651750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Furoate
Description: receiving 2 months treatment with Fluticasone Furoate nasal spray once a day
Study NCT06277908 — intervention group
Intervention type: PROCEDURE
Intervention: Elective Surgery for gastric cancer
Description: Total, distal or proximal gastrectomy via open, laparoscopic or robotic approach
Study NCT06029725 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: radiofrequency microneedling combined with 1927 nm thulium laser
Description: 1. session: radiofrequency microneedling + 1927 nm thulium laser~2. session: 1927 nm thulium laser monotherapy~3. session: 1927 nm thulium laser monotherapy
Study NCT06029725 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: radiofrequency microneedling monotherapy
Description: 1 session: radiofrequency microneedling monotherapy
Study NCT04692818 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: GE Logiq E10 clinical ultrasound scanner
Description: 2D B-mode, Doppler, and shear wave elastography images of the lesion
Study NCT04692818 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Verasonics research scanner
Description: 3D B-mode imaging, microvessel imaging, and shear wave elastography
Study NCT06679803 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Chats after Stroke (PA-ChatS)
Description: PA-ChatS consists of (1) self-monitoring step count using a Fitbit Inspire, and (2) behavioral activation for stepping activity delivered via the telephone and guided by the PA-ChatS workbook.~Participants will receive education regarding the physical activity after stroke, American Heart/Stroke Association guidelines for post-stroke physical activity levels, and an overview of the intervention activities. They will then use the Fitbit data to monitor average daily step counts, set a new step count goals (increasing by 5 to 10% of the daily average step count from the prior week), and create a specific plan for achieving the new step count goal. The interventionist will collaboratively problem solve with the participant to identify strategies to overcome barriers to stepping activity and maintain safety.
Study NCT05862818 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Day shift protocol - Diet order A-B
Description: Research participants will be assigned to day shift condition and Diet A-B order condition.
Study NCT05862818 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Day shift protocol - Diet order B-A
Description: Research participants will be assigned to day shift condition and Diet B-A order condition.
Study NCT05862818 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Night shift protocol - Diet order A-B
Description: Research participants will be assigned to simulated night shift condition and Diet A-B order condition.
Study NCT05862818 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Night shift protocol - Diet order B-A
Description: Research participants will be assigned to simulated night shift condition and Diet B-A order condition.
Study NCT06735404 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hybrid care
Description: The hybrid care model will consist of a combination of digital tools and/or task shifting of certain healthcare providers. Examples are:~* Telemonitoring: patients perform self-measurements through e.g. sensors, wearables, or (mobile) applications to get insight in their health status (supporting self-management) and report this to their healthcare provider(s), when relevant~* Teleconsultation: patients communicate with their healthcare provider(s) remotely~* Personal health portals and self-management applications~* Online prescription requests: patients request prescription online
Study NCT06734702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy
Description: The neoadjuvant regimen prior to radiotherapy consists of albumin-bound paclitaxel 260 mg/m², cisplatin 75 mg/m², and tislelizumab 200 mg, administered every 3 weeks for 2 cycles.
Study NCT06734702 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Concurrent chemoradiotherapy
Description: Definitive dose of thoracic radiotherapy with concurrent chemotherapy
Study NCT06734702 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy
Description: Definitive dose of thoracic radiotherapy with concurrent chemotherapy
Study NCT06734702 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Consolidative immunotherapy
Description: Following the completion of chemoradiotherapy, Tislelizumab consolidation therapy will be administered based on treatment efficacy and the patient's physical condition, for a total duration of 1 year, starting 1-2 months after chemoradiotherapy.
Study NCT06734702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Consolidative immunotherapy
Description: Following the completion of chemoradiotherapy, Tislelizumab consolidation therapy will be administered based on treatment efficacy and the patient's physical condition, for a total duration of 1 year, starting 1-2 months after chemoradiotherapy.
Study NCT06734598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Echo-guided Botox injection
Description: Echo-guided Botox injection to the masticatory muscles
Study NCT06734598 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: echo-guided normal saline injection
Description: echo-guided normal saline injection
Study NCT06734572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FAPIBiotin
Description: The dose will be 148-296 MBq given intravenously.
Study NCT06261086 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: evaluate serum levels pyroptosis-related indicators (GASDM-D, IL 1β & IL-18)
Description: 2 ml blood will be collected from all participants (patients and controls) by aseptic venipuncture into plain tubes. Then the samples will be allowed to coagulate during 10-20 minutes. Serum will be obtained by centrifugation at speed of 2000-3000 cycle/min for 20 minutes. Then we collect the supernatant which immediately be frozen at -80°C until analyzed to determine serum levels of pyroptosis-related indicators (GASDM-D, IL 1β \& IL-18). Serum concentration will be assessed by a commercially available double antibody sandwich enzyme-linked immunosorbent assay (ELISA) kit
Study NCT05006638 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lipid Emulsion, Intravenous
Description: Lipid emulsion is a mixture of soybean oil, egg phospholipids, glycerine, and is available in 10%, 20%, and 30% strengths. It has been used for decades as parenteral nutrition and for caloric supplementation and essential fatty acid deficiency. It has also been used as a carrier for lipid soluble medications
Study NCT05006638 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine
Description: a drug used as an antidote for some types of pesticides
Study NCT05006638 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atropine
Description: a drug used as an antidote for some types of pesticides